Vincenzo Silani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6079656/publications.pdf

Version: 2024-02-01

353 papers	20,592 citations	10986 71 h-index	14208 128 g-index
372 all docs	372 docs citations	372 times ranked	20234 citing authors

#	Article	IF	Citations
1	Genetic and epigenetic disease modifiers in an Italian C9orf72 family expressing ALS, FTD or PD clinical phenotypes. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 292-298.	1.7	5
2	A preliminary comparison between ECAS and ALS-CBS in classifying cognitiveâ€“behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients. Journal of Neurology, 2022, 269, 1899-1904.	3.6	5
3	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	1.9	39
4	COVID-19 and supra-aortic trunks disease: review of literature about critical phase and sequelae. Journal of Cardiovascular Surgery, 2022, 62, .	0.6	2
5	Role of risk scoring systems in predicting life expectancy after carotid endarterectomy in asymptomatic patients. Journal of Vascular Surgery, 2022, 75, 906-914.e4.	1.1	3
6	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
7	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
8	Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2022, 29, 1402-1409.	3.3	9
9	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
10	Oneâ€year cognitive followâ€up of COVIDâ€19 hospitalized patients. European Journal of Neurology, 2022, 29, 2006-2014.	3.3	54
11	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). Neurological Sciences, 2022, 43, 4221-4229.	1.9	1
12	Quantum Biology Research Meets Pathophysiology and Therapeutic Mechanisms: A Biomedical Perspective. Quantum Reports, 2022, 4, 148-172.	1.3	6
13	A nationwide survey on clinical neurophysiology education in Italian schools of specialization in neurology. Neurological Sciences, 2022, 43, 3407-3413.	1.9	1
14	Resting state functional brain networks associated with emotion processing in frontotemporal lobar degeneration. Molecular Psychiatry, 2022, 27, 4809-4821.	7.9	4
15	Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations. Journal of Neurology, 2022, 269, 5691-5701.	3.6	16
16	Gaze-Contingent Eye-Tracking Training in Brain Disorders: A Systematic Review. Brain Sciences, 2022, 12, 931.	2.3	6
17	Telepsychotherapy: a leaflet for psychotherapists in the age of COVID-19. A review of the evidence. Counselling Psychology Quarterly, 2021, 34, 352-367.	2.3	81
18	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56

#	Article	IF	Citations
19	Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. Neuromuscular Disorders, 2021, 31, 336-347.	0.6	13
20	A susceptibility-weighted imaging qualitative score of the motor cortex may be a useful tool for distinguishing clinical phenotypes in amyotrophic lateral sclerosis. European Radiology, 2021, 31, 1281-1289.	4.5	8
21	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 221-223.	1.9	9
22	Aortic arch types and postoperative outcomes after carotid artery stenting in asymptomatic and symptomatic patients. International Angiology, 2021, 39, 485-491.	0.9	2
23	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
24	Amyotrophic lateral sclerosis phenotypes significantly differ in terms of magnetic susceptibility properties of the precentral cortex. European Radiology, 2021, 31, 5272-5280.	4.5	9
25	Long-Lasting Cognitive Abnormalities after COVID-19. Brain Sciences, 2021, 11, 235.	2.3	107
26	Counterfactual thinking in psychiatric and neurological diseases: A scoping review. PLoS ONE, 2021, 16, e0246388.	2.5	2
27	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14
28	Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinsonâ€™s and Huntingtonâ€™s diseases. Neurological Sciences, 2021, 42, 4997-5006.	1.9	5
29	Testing olfactory dysfunction in acute and recovered COVID-19 patients: a single center study in Italy. Neurological Sciences, 2021, 42, 2183-2189.	1.9	5
30	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. Parkinsonism and Related Disorders, 2021, 84, 82-90.	2.2	2
31	Influence of contralateral carotid artery occlusions on short- and long-term outcomes of carotid artery stenting: a retrospective single-center analysis and review of literature. International Angiology, 2021, 40, 87-96.	0.9	0
32	It won't happen to me! Psychosocial factors influencing risk perception for respiratory infectious diseases: A scoping review. Applied Psychology: Health and Well-Being, 2021, 13, 835-852.	3.0	21
33	The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain, 2021, 144, 2635-2647.	7.6	33
34	Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: A meta-analysis. Pharmacological Research, 2021, 166, 105515.	7.1	24
35	Epileptic Capgras-Like Delusions in a Patient with Right Frontal Meningioma: Case Report. Case Reports in Neurology, 2021, 13, 284-288.	0.7	0
36	Unilateral freezing of gait or â€œmagnetic feet phenomenonâ€•caused by ischemic lesion involving fronto-striatal networks. Neurological Sciences, 2021, 42, 3467-3469.	1.9	0

#	Article	IF	Citations
37	A Computational Fluidâ€“Structure Interaction Study for Carotids With Different Atherosclerotic Plaques. Journal of Biomechanical Engineering, 2021, 143, .	1.3	11
38	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience, 2021, 15, 679199.	2.8	66
39	Attachment, Personality and Locus of Control: Psychological Determinants of Risk Perception and Preventive Behaviors for COVID-19. Frontiers in Psychology, 2021, 12, 634012.	2.1	25
40	Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study. Biomolecules, 2021, 11, 1220.	4.0	8
41	SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution. Molecular Neurobiology, 2021, 58, 5682-5702.	4.0	19
42	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
43	The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority. Neurological Sciences, 2021, 42, 4425-4431.	1.9	1
44	Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders. Neurology, 2021, 97, e1835-e1846.	1.1	11
45	Structural MRI Signatures in Genetic Presentations of the Frontotemporal Dementia/Motor Neuron Disease Spectrum. Neurology, 2021, 97, e1594-e1607.	1.1	19
46	Progression of cognitive and behavioral disturbances in motor neuron diseases assessed using standard and computer-based batteries. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 223-236.	1.7	6
47	Impaired recognition of disgust in amyotrophic lateral sclerosis is related to basal ganglia involvement. NeuroImage: Clinical, 2021, 32, 102803.	2.7	3
48	Prolonged cognitive deficits after COVID-19. Journal of the Neurological Sciences, 2021, 429, 119804.	0.6	1
49	The Italian dementia with lewy bodies study group (DLB-SINDEM): A multicenter survey on the accuracy and the prevalence of DLB diagnosis. Journal of the Neurological Sciences, 2021, 429, 117651.	0.6	0
50	Impaired recognition of disgust in amyotrophic lateral sclerosis is related to basal ganglia involvement. Journal of the Neurological Sciences, 2021, 429, 119376.	0.6	0
51	Emotional Processing and Experience in Amyotrophic Lateral Sclerosis: A Systematic and Critical Review. Brain Sciences, 2021, 11, 1356.	2.3	6
52	Converging longitudinal patterns of atrophy in clinical variants of frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2021, 429, 118296.	0.6	0
53	The unfolded protein response in amyotrophic later sclerosis: Results of a phase 2 trial. Journal of the Neurological Sciences, 2021, 429, 117702.	0.6	0
54	Structural MRI signatures of grey matter atrophy in genetic frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2021, 429, 117777.	0.6	0

#	Article	IF	Citations
55	Clinical and genetic spectrum of amyotrophic lateral sclerosis in a Tunisian series. Journal of the Neurological Sciences, 2021, 429, 119402.	0.6	0
56	SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Communications, 2021, 3, fcab236.	3.3	14
57	Epileptic capgras-like delusions in a patient with right frontal meningioma. Case report. Journal of the Neurological Sciences, 2021, 429, 119106.	0.6	0
58	Clinically evident ocular movement abnormalities are specific for cognitive impairment in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117706.	0.6	0
59	Pallidal functional connectivity changes are associated with disgust recognition in pure motor amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117703.	0.6	0
60	Prominent upper motor neuron dysfunction correlates with a more significant behavioral impairment in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117744.	0.6	1
61	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
62	Brain MRI signatures of atrophy in genetic frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, .	0.8	0
63	Converging longitudinal patterns of atrophy in clinical variants of frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, .	0.8	0
64	Impaired recognition of disgust is related to subcortical volume loss in amyotrophic lateral sclerosis. Alzheimer's and Dementia, 2021, 17, .	0.8	0
65	Identification of the Raman Salivary Fingerprint of Parkinsonâ€™s Disease Through the Spectroscopicâ€“ Computational Combinatory Approach. Frontiers in Neuroscience, 2021, 15, 704963.	2.8	12
66	Carotid artery stenting is safe and effective for symptomatic patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2020, 96, 129-135.	1.7	1
67	CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 63-69.	1.7	6
68	Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiology of Disease, 2020, 145, 105051.	4.4	52
69	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Communications, 2020, 2, fcaa142.	3.3	55
70	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1001-1003.	1.9	14
71	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
72	New technologies and Amyotrophic Lateral Sclerosis â€“ Which step forward rushed by the COVID-19 pandemic?. Journal of the Neurological Sciences, 2020, 418, 117081.	0.6	36

#	Article	IF	Citations
73	Fiberoptic endoscopic evaluation of swallowing in early-to-advanced stage Huntingtonâ€™s disease. Scientific Reports, 2020, 10, 15242.	3.3	10
74	Progression of brain functional connectivity and frontal cognitive dysfunction in ALS. NeuroImage: Clinical, 2020, 28, 102509.	2.7	19
75	An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID). Neurological Sciences, 2020, 41, 1355-1359.	1.9	46
76	Neurology and the COVID-19 emergency. Neurological Sciences, 2020, 41, 1343-1344.	1.9	8
77	Rising evidence for neurological involvement in COVID-19 pandemic. Neurological Sciences, 2020, 41, 1339-1341.	1.9	25
78	Advance care planning and mental capacity in ALS: a current challenge for an unsolved matter. Neurological Sciences, 2020, 41, 2997-2998.	1.9	4
79	Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Scientific Reports, 2020, 10, 10175.	3.3	37
80	Reprogramming fibroblasts and peripheral blood cells from a C9ORF72 patient: A proofâ€ofâ€principle study. Journal of Cellular and Molecular Medicine, 2020, 24, 4051-4060.	3.6	8
81	Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2020, 27, 102315.	2.7	14
82	Cervical transverse MRI in ALS diagnosis and possible link to VEGF and MMP9 single nucleotide polymorphisms. Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 814-816.	0.6	0
83	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
84	Toward a marker of upper motor neuron impairment in amyotrophic lateral sclerosis: A fully automatic investigation of the magnetic susceptibility in the precentral cortex. European Journal of Radiology, 2020, 124, 108815.	2.6	15
85	Genetics of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 28-34.	1.7	13
86	Preface: promoting research in PLS: current knowledge and future challenges. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 1-2.	1.7	6
87	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	1.9	118
88	TDP-43 and NOVA-1 RNA-binding proteins as competitive splicing regulators of the schizophrenia-associated TNIK gene. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 194413.	1.9	9
89	A Novel Approach for Investigating Parkinsonâ€™s Disease Personality and Its Association With Clinical and Psychological Aspects. Frontiers in Psychology, 2019, 10, 2265.	2.1	2
90	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Frontiers in Neuroscience, 2019, 13, 485.	2.8	35

#	Article	IF	Citations
91	Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open, 2019, 9, e028486.	1.9	44
92	PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survival. Neurological Sciences, 2019, 40, 1469-1473.	1.9	14
93	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
94	Three-year outcomes after carotid artery revascularization: Gender-related differences. Vascular, 2019, 27, 459-467.	0.9	5
95	Inter-Species Differences in Regulation of the Progranulinâ€“Sortilin Axis in TDP-43 Cell Models of Neurodegeneration. International Journal of Molecular Sciences, 2019, 20, 5866.	4.1	3
96	A Novel Mutation of GFAP Causing Adult-Onset Alexander Disease. Frontiers in Neurology, 2019, 10, 1124.	2.4	7
97	Neurochemical biomarkers in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2019, 32, 747-757.	3.6	24
98	Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation. Neurological Sciences, 2019, 40, 515-521.	1.9	19
99	Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 531-536.	2.2	40
100	Response to the commentary â€œThe effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseasesâ€•by Biasiotto G and Zanella I.âœ°. Multiple Sclerosis and Related Disorders, 2019, 27, 79-80.	2.0	1
101	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	1.9	174
102	Does metabolic syndrome influence short and long term durability of carotid endarterectomy and stenting?. Diabetes/Metabolism Research and Reviews, 2019, 35, e3084.	4.0	11
103	Sexuality and intimacy in ALS: systematic literature review and future perspectives. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 712-719.	1.9	10
104	Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. European Journal of Neurology, 2018, 25, 861-868.	3.3	29
105	Characterization of the c9orf72 GC-rich low complexity sequence in two cohorts of Italian and Turkish ALS cases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 426-431.	1.7	2
106	Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 331-341.	1.7	31
107	Is diabetes a marker of higher risk after carotid revascularization? Experience from a single centre. Diabetes and Vascular Disease Research, 2018, 15, 314-321.	2.0	10
108	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	3.1	6

#	Article	IF	Citations
109	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
110	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
111	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148
112	Do Women Have a Higher Risk of Adverse Events after Carotid Revascularization?. , 2018, , .		1
113	The Arrows and Colors Cognitive Test (ACCT): A new verbal-motor free cognitive measure for executive functions in ALS. PLoS ONE, 2018, 13, e0200953.	2.5	15
114	Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 387-395.	1.7	34
115	Motor neuron differentiation of iPSCs obtained from peripheral blood of a mutant TARDBP ALS patient. Stem Cell Research, 2018, 30, 61-68.	0.7	21
116	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiology of Aging, 2018, 71, 266.e1-266.e10.	3.1	59
117	The Complex Interplay Between Depression/Anxiety and Executive Functioning: Insights From the ECAS in a Large ALS Population. Frontiers in Psychology, 2018, 9, 450.	2.1	14
118	Genotypic and Phenotypic Heterogeneity in Amyotrophic Lateral Sclerosis. , 2018, , 279-295.		3
119	No C9orf72 repeat expansion in patients with primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 192-195.	2.0	9
120	The emerging picture of ALS: a multisystem, not only a â€œmotor neuron diseaseâ€• Archives Italiennes De Biologie, 2018, 155, 153-158.	0.4	17
121	Therapy in Amyotrophic Lateral Sclerosis (ALS): an unexpected evolving scenario. Archives Italiennes De Biologie, 2018, 155, 228-241.	0.4	15
122	Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2017, 53, 195.e1-195.e5.	3.1	17
123	An eye-tracking controlled neuropsychological battery for cognitive assessment in neurological diseases. Neurological Sciences, 2017, 38, 595-603.	1.9	17
124	An eye-tracker controlled cognitive battery: overcoming verbal-motor limitations in ALS. Journal of Neurology, 2017, 264, 1136-1145.	3.6	27
125	Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Annals of Neurology, 2017, 81, 837-848.	5.3	32
126	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	129

#	Article	IF	Citations
127	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp>C9ORF</scp>72â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	5.3	88
128	Inefficient skeletal muscle oxidative function flanks impaired motor neuron recruitment in Amyotrophic Lateral Sclerosis during exercise. Scientific Reports, 2017, 7, 2951.	3.3	12
129	Adiponectin levels in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients: possible influence on neuroinflammation?. Journal of Neuroinflammation, 2017, 14, 85.	7.2	3
130	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
131	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 153-174.	1.7	607
132	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
133	Use of Noninvasive Ventilation During Feeding Tube Placement. Respiratory Care, 2017, 62, 1474-1484.	1.6	14
134	The role of de novo mutations in the development of amyotrophic lateral sclerosis. Human Mutation, 2017, 38, 1534-1541.	2.5	13
135	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open, 2017, 7, e015434.	1.9	14
136	Safety and Efficacy of the New Micromesh-Covered Stent CGuard in Patients Undergoing Carotid Artery Stenting: Early Experience From a Single Centre. European Journal of Vascular and Endovascular Surgery, 2017, 54, 681-687.	1.5	25
137	The synaptic function of parkin. Brain, 2017, 140, 2265-2272.	7.6	42
138	Factors predicting survival in ALS: a multicenter Italian study. Journal of Neurology, 2017, 264, 54-63.	3.6	96
139	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurological Sciences, 2017, 38, 83-91.	1.9	11
140	X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene. Parkinsonism and Related Disorders, 2017, 44, 142-146.	2.2	43
141	Cognitive-constructivist Approach in Medical Settings: The Use of Personal Meaning Questionnaire for Neurological Patientsâ€™ Personality Investigation. Frontiers in Psychology, 2017, 08, 582.	2.1	4
142	Neuropsychiatric Burden in Huntingtonâ€™s Disease. Brain Sciences, 2017, 7, 67.	2.3	90
143	Brain-Computer Interface for Clinical Purposes: Cognitive Assessment and Rehabilitation. BioMed Research International, 2017, 2017, 1-11.	1.9	83
144	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Frontiers in Immunology, 2016, 7, 5.	4.8	30

#	Article	IF	Citations
145	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. Journal of Hypertension, 2016, 34, 393-396.	0.5	26
146	Cognitive assessment in Amyotrophic Lateral Sclerosis by means of P300-Brain Computer Interface: a preliminary study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 473-481.	1.7	12
147	MRI abnormalities found 1Âyear prior to symptom onset in a case of Creutzfeldtâ€“Jakob disease. Journal of Neurology, 2016, 263, 597-599.	3.6	11
148	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
149	Cerebral microbleeds: A new presenting feature of chromosome 22q11.2 deletion syndrome. Journal of the Neurological Sciences, 2016, 368, 300-303.	0.6	4
150	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
151	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218
152	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	12.8	174
153	You stole my food! Eating alterations in frontotemporal dementia. Neurocase, 2016, 22, 400-409.	0.6	15
154	The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 489-498.	1.7	125
155	Association of a Locus in theCAMTA1Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
156	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathologica Communications, 2016, 4, 47.	5.2	147
157	Phenotypic Modulation and Neuroprotective Effects of Olfactory Ensheathing Cells: a Promising Tool for Cell Therapy. Stem Cell Reviews and Reports, 2016, 12, 224-234.	5.6	20
158	Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 810-816.	1.9	59
159	Counterfactual Thinking Deficit in Huntingtonâ€™s Disease. PLoS ONE, 2015, 10, e0126773.	2.5	8
160	Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3) has a key role in the mitochondrial dysfunction induced by mutant huntingtin. Human Molecular Genetics, 2015, 24, 6530-6539.	2.9	13
161	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. Neurological Sciences, 2015, 36, 751-757.	1.9	9
162	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science, 2015, 347, 1436-1441.	12.6	823

#	Article	IF	Citations
163	TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations. Journal of Neurology, 2015, 262, 1376-1378.	3.6	44
164	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
165	From transcriptomic to protein level changes in TDP-43 and FUS loss-of-function cell models. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 1398-1410.	1.9	38
166	Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy. Acta Neuropathologica, 2015, 130, 373-387.	7.7	27
167	CHCHD10mutations in Italian patients with sporadic amyotrophic lateral sclerosis: Figure 1. Brain, 2015, 138, e372-e372.	7.6	59
168	A Review of Options for Treating Sialorrhea in Amyotrophic Lateral Sclerosis. Respiratory Care, 2015, 60, 446-454.	1.6	64
169	Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiology of Aging, 2015, 36, 1602.e17-1602.e27.	3.1	87
170	Editorial on the original article entitled "Genetic validation of a therapeutic target in a mouse model of ALS" published in the Science Translational Medicine on August 6, 2014. Annals of Translational Medicine, 2015, 3, S27.	1.7	0
171	Parkin regulates kainate receptors by interacting with the GluK2 subunit. Nature Communications, 2014, 5, 5182.	12.8	42
172	An old woman with pressure ulcer, rigidity, and opisthotonus: never forget tetanus!. Lancet, The, 2014, 384, 2266.	13.7	7
173	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. Journal of Hypertension, 2014, 32, 1741-1750.	0.5	39
174	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
175	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	3.2	118
176	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 2220-2231.	2.9	123
177	Resting state functional connectivity alterations in primary lateral sclerosis. Neurobiology of Aging, 2014, 35, 916-925.	3.1	41
178	Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?. Lancet Neurology, The, 2014, 13, 1127-1138.	10.2	240
179	Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. Neuron, 2014, 84, 324-331.	8.1	308
180	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050.	8.1	289

#	Article	IF	Citations
181	<scp>C9orf72</scp> and <scp>UNC13A</scp> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genomeâ€wide metaâ€analysis. Annals of Neurology, 2014, 76, 120-133.	5.3	91
182	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiology of Aging, 2014, 35, 408-417.	3.1	36
183	C9orf72 repeat expansions are restricted to the ALS-FTD spectrum. Neurobiology of Aging, 2014, 35, 936.e13-936.e17.	3.1	28
184	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 344-350.	1.7	62
185	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. Human Brain Mapping, 2014, 35, 1710-1722.	3.6	76
186	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. Journal of Hypertension, 2014, 32, 1888-1897.	0.5	65
187	Amyotrophic Lateral Sclerosis: Genotypes and Phenotypes. , 2014, , 179-192.		1
188	Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurology, 2013, 13, 84.	1.8	90
189	Charles Bonnet syndrome: two case reports and review of the literature. Journal of Neurology, 2013, 260, 1180-1186.	3.6	25
190	Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. Acta Neuropathologica, 2013, 126, 109-121.	7.7	41
191	ELAV proteins along evolution: Back to the nucleus?. Molecular and Cellular Neurosciences, 2013, 56, 447-455.	2.2	67
192	Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings. Acta Neurologica Scandinavica, 2013, 128, 397-401.	2.1	102
193	Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. Journal of Neurology, 2013, 260, 85-92.	3.6	24
194	Neurorescue effects and stem properties of chorionic villi and amniotic progenitor cells. Neuroscience, 2013, 234, 158-172.	2.3	28
195	Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiology of Aging, 2013, 34, 1517.e9-1517.e10.	3.1	35
196	Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2013, 34, 2695.e11-2695.e12.	3.1	30
197	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.7	68
198	Biocompatible fluorescent nanoparticles forin vivostem cell tracking. Nanotechnology, 2013, 24, 245603.	2.6	29

#	Article	IF	Citations
199	Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions. Journal of Clinical Neuroscience, 2013, 20, 134-138.	1.5	6
200	Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology, 2013, 80, 2095-2098.	1.1	47
201	The C9ORF72 expansion mutation is a common cause of ALS+/â^'FTD in Europe and has a single founder. European Journal of Human Genetics, 2013, 21, 102-108.	2.8	201
202	Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats. Journal of Hypertension, 2013, 31, 1618-1628.	0.5	5
203	Ubiquilin 2mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 183-187.	1.9	74
204	Carotid Artery Stenting in Patients With Acute Coronary Syndrome: A Possible Primary Therapy for Symptomatic Carotid Stenosis. Journal of Endovascular Therapy, 2013, 20, 546-551.	1.5	8
205	No evidence of cardiomyopathy in spinal and bulbar muscular atrophy. Acta Neurologica Scandinavica, 2013, 128, e30-e32.	2.1	14
206	Wake-up stroke and TIA due to paradoxical embolism during long obstructive sleep apnoeas: a cross-sectional study. Thorax, 2013, 68, 97-104.	5.6	39
207	Defining the role of the Bcl-2 family proteins in Huntingtonâ€™s disease. Cell Death and Disease, 2013, 4, e772-e772.	6.3	32
208	Dose Dependent Side Effect of Superparamagnetic Iron Oxide Nanoparticle Labeling on Cell Motility in Two Fetal Stem Cell Populations. PLoS ONE, 2013, 8, e78435.	2.5	33
209	Extramotor Damage Is Associated with Cognition in Primary Lateral Sclerosis Patients. PLoS ONE, 2013, 8, e82017.	2.5	33
210	Cognitive assessment of executive functions using brain computer interface and eye-tracking. EAI Endorsed Transactions on Ambient Systems, 2013, 13, e4.	0.3	8
211	Validating the Neuro VR-Based Virtual Version of the Multiple Errands Test: Preliminary Results. Presence: Teleoperators and Virtual Environments, 2012, 21, 31-42.	0.6	55
212	Molecular Signatures of Amyotrophic Lateral Sclerosis Disease Progression in Hind and Forelimb Muscles of an SOD1^{G93A} Mouse Model. Antioxidants and Redox Signaling, 2012, 17, 1333-1350.	5.4	65
213	TDP-43 and FUS RNA-binding Proteins Bind Distinct Sets of Cytoplasmic Messenger RNAs and Differently Regulate Their Post-transcriptional Fate in Motoneuron-like Cells. Journal of Biological Chemistry, 2012, 287, 15635-15647.	3.4	233
214	Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 265-269.	2.1	15
215	Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature, 2012, 488, 499-503.	27.8	522
216	Mutational analysis of VCP gene in familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 630.e1-630.e2.	3.1	17

#	Article	IF	Citations
217	ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiology of Aging, 2012, 33, 1847.e15-1847.e21.	3.1	27
218	C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. Neurobiology of Aging, 2012, 33, 2528.e7-2528.e14.	3.1	74
219	Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson’s disease. International Journal of Nanomedicine, 2012, 7, 435.	6.7	25
220	The use of P300â€based BCIs in amyotrophic lateral sclerosis: from augmentative and alternative communication to cognitive assessment. Brain and Behavior, 2012, 2, 479-498.	2.2	53
221	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) â€“ revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
222	Impaired expression of insulinâ€like growth factorâ€1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle and Nerve, 2012, 45, 200-208.	2.2	43
223	Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinsonâ€™s disease. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 289-304.	4.9	28
224	Longitudinal Tracking of Human Fetal Cells Labeled with Super Paramagnetic Iron Oxide Nanoparticles in the Brain of Mice with Motor Neuron Disease. PLoS ONE, 2012, 7, e32326.	2.5	28
225	Intracerebroventricular Administration of Human Umbilical Cord Blood Cells Delays Disease Progression in Two Murine Models of Motor Neuron Degeneration. Rejuvenation Research, 2011, 14, 623-639.	1.8	44
226	Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: Case report and review of the literature. Journal of the Neurological Sciences, 2011, 301, 107-111.	0.6	19
227	No association of DPP6 with amyotrophic lateral sclerosis in an Italian population. Neurobiology of Aging, 2011, 32, 966-967.	3.1	28
228	Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiology of Aging, 2011, 32, 2096-2099.	3.1	43
229	Ultrastructural Mitochondrial Abnormalities in Patients With Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 1612.	4.5	16
230	The combined use of Brain Computer Interface and Eye-Tracking technology for cognitive assessment in Amyotrophic Lateral Sclerosis. , 2011, , .		17
231	VPS54 genetic analysis in ALS Italian cohort. European Journal of Neurology, 2011, 18, e41-e42.	3.3	6
232	Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. Movement Disorders, 2011, 26, 130-137.	3.9	52
233	Repeated courses of granulocyte colonyâ€stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle and Nerve, 2011, 43, 189-195.	2.2	64
234	Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 285-290.	1.7	148

#	Article	IF	Citations
235	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	5.3	168
236	The Survival of Motor Neuron (SMN) Protein Interacts with the mRNA-Binding Protein HuD and Regulates Localization of Poly(A) mRNA in Primary Motor Neuron Axons. Journal of Neuroscience, 2011, 31, 3914-3925.	3.6	197
237	Endovascular Management of Symptomatic Cerebral Malperfusion Due to Carotid Dissection After Type A Aortic Dissection Repair. Vascular and Endovascular Surgery, 2011, 45, 641-645.	0.7	13
238	Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1239-1243.	1.9	86
239	The diagnosis of Amyotrophic lateral sclerosis in 2010. Archives Italiennes De Biologie, 2011, 149, 5-27.	0.4	25
240	RNA-binding proteins and RNA metabolism: a new scenario in the pathogenesis of Amyotrophic lateral sclerosis. Archives Italiennes De Biologie, 2011, 149, 83-99.	0.4	26
241	Genetics of familial Amyotrophic lateral sclerosis. Archives Italiennes De Biologie, 2011, 149, 65-82.	0.4	70
242	Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). Archives Italiennes De Biologie, 2011, 149, 39-56.	0.4	36
243	Introducing Amyotrophic lateral sclerosis. Archives Italiennes De Biologie, 2011, 149, 1-4.	0.4	18
244	Mitochondrial Respiratory Chain Dysfunction in Muscle From Patients With Amyotrophic Lateral Sclerosis. Archives of Neurology, 2010, 67, 849-54.	4.5	122
245	Transplantation of Undifferentiated Human Mesenchymal Stem Cells Protects against 6-Hydroxydopamine Neurotoxicity in the Rat. Cell Transplantation, 2010, 19, 203-218.	2.5	136
246	COGNITIVE FUNCTION UNDER EXPOSURE TO HYPOBARIC HYPOXIA AT ALTITUDE: DATA FROM THE HIGHCARE PROJECT: PP.4.136. Journal of Hypertension, 2010, 28, e89.	0.5	0
247	A13â€...Mutant huntingtin induces activation of Bcl-2/adenovirus E1B 19-kDa interacting protein (BNIP3). Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A4.3-A4.	1.9	0
248	Metalloproteinase alterations in the bone marrow of ALS patients. Journal of Molecular Medicine, 2010, 88, 553-564.	3.9	30
249	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology, The, 2010, 9, 986-994.	10.2	205
250	Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Research, 2010, 1311, 12-27.	2.2	129
251	Paraoxonase gene mutations in amyotrophic lateral sclerosis. Annals of Neurology, 2010, 68, 102-107.	5.3	67
252	Free insulinâ€like growth factor (IGF)â€1 and IGFâ€binding proteinsâ€2 and â€3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. European Journal of Neurology, 2010, 17, 398-404.	3.3	19

#	Article	IF	Citations
253	EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. European Journal of Neurology, 2010, 17, 526.	3.3	75
254	Amyotrophic lateral sclerosis: applications of stem cells – an update. Stem Cells and Cloning: Advances and Applications, 2010, 3, 145.	2.3	7
255	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.1	90
256	Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2010, 47, 190-194.	3.2	152
257	Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3). Cell Death and Disease, 2010, 1, e7-e7.	6.3	24
258	The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis. American Journal of Neuroradiology, 2010, 31, 1769-1777.	2.4	124
259	Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyteâ€“colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy, 2010, 12, 50-59.	0.7	36
260	Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage. CNS and Neurological Disorders - Drug Targets, 2010, 9, 285-296.	1.4	37
261	Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?. CNS and Neurological Disorders - Drug Targets, 2010, 9, 314-324.	1.4	21
262	Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. European Journal of Inflammation, 2009, 7, 39-44.	0.5	12
263	Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology, 2009, 73, 1180-1185.	1.1	139
264	IPLEX and the Telephone Game: The difficulty in separating myth from reality on the internet. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 182-184.	2.1	4
265	Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9004-9009.	7.1	177
266	High frequency ofTARDBPgene mutations in Italian patients with amyotrophic lateral sclerosis. Human Mutation, 2009, 30, 688-694.	2.5	184
267	TDPâ€43 is recruited to stress granules in conditions of oxidative insult. Journal of Neurochemistry, 2009, 111, 1051-1061.	3.9	435
268	Huntington's disease: The current state of research with peripheral tissues. Experimental Neurology, 2009, 219, 385-397.	4.1	154
269	Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 378-383.	2.1	83
270	Obstructive Sleep Apnea Syndrome: A Cause of Acute Delirium. Journal of Clinical Sleep Medicine, 2009, 05, 569-570.	2.6	18

#	Article	IF	Citations
271	Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics, 2008, 9, 33-40.	1.4	102
272	Stem cell transplantation in Multiple Sclerosis: Safety and Ethics. Journal of the Neurological Sciences, 2008, 265, 116-121.	0.6	18
273	Post-transcriptional Regulation of Neuro-oncological Ventral Antigen 1 by the Neuronal RNA-binding Proteins ELAV. Journal of Biological Chemistry, 2008, 283, 7531-7541.	3.4	56
274	WHAT IS NEXT IN ALS CLINICAL TRIALS?. Neurology, 2008, 70, 1365-1366.	1.1	1
275	Molecular and phenotypical characterization of human amniotic fluid cells and their differentiation potential. Bio-Medical Materials and Engineering, 2008, 18, 183-185.	0.6	3
276	WHAT IS NEXT IN ALS CLINICAL TRIALS?. Neurology, 2008, 70, 1366-1367.	1.1	1
277	Dysgraphia in Patients with Primary Lateral Sclerosis: A Speech-Based Rehearsal Deficit?. Behavioural Neurology, 2008, 19, 169-175.	2.1	16
278	Phase II/III randomized trial of TCH346 in patients with ALS. Neurology, 2007, 69, 776-784.	1.1	112
279	Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 217-223.	2.1	98
280	Induction of Neurotrophin Expression via Human Adult Mesenchymal Stem Cells: Implication for Cell Therapy in Neurodegenerative Diseases. Cell Transplantation, 2007, 16, 41-55.	2.5	97
281	Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidenceâ€based review with good practice points. EALSC Working Group. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 195-213.	2.1	168
282	Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 574-577.	1.7	142
283	Age at onset in sod1-mediated amyotrophic lateral sclerosis shows familiality. Neurogenetics, 2007, 8, 235-236.	1.4	14
284	Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death and Differentiation, 2006, 13, 2068-2078.	11.2	81
285	Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Research, 2006, 16, 329-336.	12.0	175
286	A role for the ELAV RNA-binding proteins in neural stem cells: stabilization of Msi1 mRNA. Journal of Cell Science, 2006, 119, 1442-1452.	2.0	89
287	Apoptosis induced by proteasome inhibition in human myoblast cultures. European Journal of Histochemistry, 2006, 50, 109-18.	1.5	4
288	EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. An evidence-based review with good practice points. European Journal of Neurology, 2005, 12, 921-938.	3.3	261

#	Article	IF	Citations
289	Production of monocyte chemoattractant proteinâ€1 in amyotrophic lateral sclerosis. Muscle and Nerve, 2005, 32, 541-544.	2.2	104
290	Neuro-glial differentiation of human bone marrow stem cells in vitro. Experimental Neurology, 2005, 193, 312-325.	4.1	190
291	Cell-Replacement Therapy with Stem Cells in Neurodegenerative Diseases. Current Neurovascular Research, 2004, 1, 283-289.	1.1	19
292	Stem Cell Therapy for Neurodegenerative Diseases: The Issue of Transdifferentiation. Stem Cells and Development, 2004, 13, 121-131.	2.1	27
293	Stem-cell therapy for amyotrophic lateral sclerosis. Lancet, The, 2004, 364, 200-202.	13.7	96
294	Stem Cell Therapy for ALS: Hope and RealityA discussion paper from the Executive of the European ALS Consortium. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 8-10.	1.2	18
295	Stem therapy for ALS: hope and reality. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 8-10.	1.2	1
296	Stem cells in the treatment of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 173-181.	1.2	16
297	Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. Journal of the Neurological Sciences, 2001, 191, 145-150.	0.6	50
298	Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. Journal of the Neurological Sciences, 2001, 191, 25-33.	0.6	185
299	Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease. Science, 2001, 293, 493-498.	12.6	1,191
300	Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. Neuromuscular Disorders, 2001, 11, 404-410.	0.6	47
301	Human developing motor neurons as a tool to study ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 69-76.	1.2	4
302	Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 159-164.	1.2	87
303	The pathogenesis of ALS: implications for treatment strategies. Neurologia I Neurochirurgia Polska, 2001, 35, 25-39.	1.2	2
304	Motor neurones in culture as a model to study ALS. Journal of Neurology, 2000, 247, I28-I36.	3.6	18
305	A tentative interpretation of electromyographic regional differences in bulbar- and limb-onset ALS. Neurology, 2000, 54, 536-536.	1.1	1
306	Bartolomeo Panizza and the Discovery of the Brain's Visual Center. Archives of Neurology, 2000, 57, 1642-8.	4.5	13

#	Article	IF	Citations
307	Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscular Disorders, 2000, 10, 391-397.	0.6	112
308	Macular preservation with bilateral visual field defect caused by embolic occlusion of the posterior cerebral arteries. Journal of Neurology, 1999, 246, 55-57.	3.6	0
309	Motor neurone metabolism. Journal of the Neurological Sciences, 1999, 169, 161-169.	0.6	14
310	Isolation and Characterization of a Novel Transcript Embedded within HIRA, a Gene Deleted in DiGeorge Syndrome. Molecular Genetics and Metabolism, 1999, 67, 227-235.	1.1	22
311	Honesty and hope: announcement of diagnosis in ALS. Neurology, 1999, 53, S37-9; discussion S40-2.	1.1	18
312	Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. Journal of Neurology, 1998, 245, S13-S19.	3.6	61
313	A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology, 1998, 51, 583-586.	1.1	333
314	Immunomagnetic isolation of human developing motor neurons. NeuroReport, 1998, 9, 1143-1147.	1.2	12
315	UFD1L, a Developmentally Expressed Ubiquitination Gene, is Deleted in CATCH 22 Syndrome. Human Molecular Genetics, 1997, 6, 259-265.	2.9	85
316	Expression Study of Survival Motor Neuron Gene in Human Fetal Tissues. Biochemical and Molecular Medicine, 1997, 61, 102-106.	1.4	31
317	Morphological differentiation of astroglial progenitor cells from EGF-responsive neurospheres in response to fetal calf serum, basic fibroblast growth factor, and retinol. Cell Transplantation, 1996, 5, 179-189.	2.5	26
318	Ras P21 protein promotes survival and differentiation of human embryonic neural crest-derived cells. Neuroscience, 1996, 73, 1121-1127.	2.3	18
319	Clinical and pathological features in hydrocarbon-induced Parkinsonism. Annals of Neurology, 1996, 40, 922-925.	5.3	37
320	Deletion analysis of the simple tandem repeat loci physically linked to the spinal muscular atrophy locus. Human Mutation, 1996, 7, 198-201.	2.5	7
321	cDNA characterization and chromosomal mapping of two human homologues of the Drosophila dishevelled polarity gene. Human Molecular Genetics, 1996, 5, 953-958.	2.9	57
322	Human homologue sequences to the Drosophila dishevelled segment-polarity gene are deleted in the DiGeorge syndrome. American Journal of Human Genetics, 1996, 58, 722-9.	6.2	39
323	Human substantia nigra in vitro as a bioassay for neurotrophic molecules of clinical significance. Advances in Neurology, 1996, 69, 253-62.	0.8	1
324	Postzygotic instability of the myotonic dystrophy p[AGC]n repeat supported by larger expansions in muscle and reduced amplifications in sperm. Journal of Neurology, 1995, 242, 379-383.	3.6	13

#	Article	IF	Citations
325	Identification of Multiple Transcribed Sequences from the Spinal Muscular Atrophy Region on Human Chromosome 5. Biochemical and Biophysical Research Communications, 1995, 206, 294-301.	2.1	7
326	Molecules with neurotrophic effects on the human developing mesencephalic dopaminergic neurons. Journal of Neural Transmission Supplementum, 1995, 45, 287-96.	0.5	0
327	High conservation of the trinucleotide [CTG]n repeat at the myotonic dystrophy locus in nonhuman primates. Human Evolution, 1994, 9, 315-321.	2.0	0
328	Development of Dopaminergic Neurons in the Human Mesencephalon and in Vitro Effects of Basic Fibroblast Growth Factor Treatment. Experimental Neurology, 1994, 128, 59-76.	4.1	32
329	NGF-response of EGF-dependent progenitor cells obtained from human sympathetic ganglia. NeuroReport, 1994, 5, 2085-2089.	1.2	8
330	Ganglioside GM1 expression during human spinal cord and neural crest development. NeuroReport, 1993, 4, 767-770.	1.2	11
331	Acquisition of the Immunophenotype by Human Adrenal Cells. Journal of Neural Transplantation & Plasticity, 1992, 3, 211-212.	0.7	0
332	Human fetal brain Î²-nerve growth factor cDNA: molecular cloning of 5â€² and 3â€² untranslated regions. Neuroscience Letters, 1991, 127, 117-120.	2.1	2
333	Î²-Nerve growth factor (Î²-NGF) mRNA expression in the Parkinsonian adrenal gland. Experimental Neurology, 1991, 113, 166-170.	4.1	12
334	Chapter 76 Adrenal medulla autograft in 3 parkinsonian patients: results using two different approaches. Progress in Brain Research, 1990, 82, 677-682.	1.4	5
335	Effect of nerve growth factor in adrenal autografts in parkinsonism. Annals of Neurology, 1990, 27, 341-342.	5.3	109
336	Detection of Î²-nerve growth factor mRNA in the human fetal brain. Brain Research, 1990, 518, 337-341.	2.2	11
337	cDNA sequence of human Î²-NGF. Nucleic Acids Research, 1990, 18, 4020-4020.	14.5	12
338	Human neuronal cell viability demonstrated in culture after cryopreservation. Brain Research, 1988, 473, 169-174.	2.2	51
339	Cryopreservation of human fetal adrenal medullary cells. Brain Research, 1988, 454, 383-386.	2.2	10
340	SURGICAL LESIONS, PARKINSONISM, AND BRAIN GRAFT OPERATIONS. Lancet, The, 1988, 332, 346.	13.7	17
341	Chapter 71 Characterization of purified populations of human fetal chromaffin cells: considerations for grafting in parkinsonian patients. Progress in Brain Research, 1988, 78, 551-557.	1.4	3
342	Human Fetal Adrenal Medulla for Transplantation in Parkinsonian Patients. Annals of the New York Academy of Sciences, 1987, 495, 771-773.	3.8	4

#	Article	IF	Citations
343	Neuroimmunology of human fetal brain in tissue culture. International Journal of Developmental Neuroscience, 1985, 3, 451-451.	1.6	0
344	Manifesting carrier of X-linked Duchenne muscular dystrophy. Journal of the Neurological Sciences, 1981, 49, 455-463.	0.6	16
345	Metabolic impairment and membrane abnormality in red cells from Huntington's disease. Journal of the Neurological Sciences, 1980, 47, 93-103.	0.6	35
346	Erythrocyte spectrofluorometric abnormalities in Duchenne patients and carriers. Acta Neurologica Scandinavica, 1979, 59, 262-269.	2.1	10
347	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
348	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. SSRN Electronic Journal, 0, , .	0.4	1
349	Mutations in the Sphingolipid Pathway Gene <i>SPTLC1</i> are a Cause of Amyotrophic Lateral Sclerosis. SSRN Electronic Journal, 0, , .	0.4	0
350	Neurological manifestations: an overview. , 0, , 45-54.		0
351	Parkinsonian Syndromes in Motor Neuron Disease: A Clinical Study. Frontiers in Aging Neuroscience, 0, 14, .	3.4	7
352	Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations. Frontiers in Neurology, 0, 13, .	2.4	5
353	Expanding the phenotype of TARDBP mutation in a Tunisian family with clinical phenotype heterogeneity. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 0, , 1-4.	1.7	1